Clinical trials
Withdrawn trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
490 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 14 |
| 2012 | 7 |
| 2013 | 9 |
| 2014 | 11 |
| 2015 | 25 |
| 2016 | 22 |
| 2017 | 36 |
| 2018 | 37 |
| 2019 | 30 |
| 2020 | 36 |
| 2021 | 46 |
| 2022 | 43 |
| 2023 | 36 |
| 2024 | 64 |
| 2025 | 31 |
| 2026 | 26 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 490 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-sen University | 33 |
| Children's Hospital of Fudan University | 19 |
| Fuda Cancer Hospital, Guangzhou | 18 |
| Zeng Changhao | 17 |
| Beijing Boren Hospital | 13 |
| Shandong University | 10 |
| Peking University People's Hospital | 8 |
| Fudan University | 7 |
| Ruijin Hospital | 7 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 7 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Hepatocellular | 24 |
| Lung Neoplasms | 17 |
| Colorectal Neoplasms | 14 |
| Breast Neoplasms | 13 |
| COVID-19 | 13 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Recurrence | 13 |
| Purpura, Thrombocytopenic, Idiopathic | 11 |
| Esophageal Neoplasms | 9 |
| Lymphoma, B-Cell | 9 |
Trials
Showing 1 to 25 of 490. Each trial links to its page on Pharma Observatory.
390 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.